KRAS and Patent ductus arteriosus: First, MEK inhibitors (MEKi) are particularly suitable for targeting Kras-driven pancreatic ductal adenocarcinoma (PDA) tumor cells as well as other tumor cells lines with activated MAPK/ERK signaling.